{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000034","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.146132+00:00","generated_at":"2026-05-28T03:21:43.892957+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Summit Therapeutics reports preliminary cash ≥$410M as of Dec 31, 2024","bullets":["Preliminary unaudited cash, cash equivalents, and short-term investments at least $410M.","Includes repayment of $31.8M related party loan (principal + interest) previously outstanding.","Amount is preliminary and subject to completion of year-end financial closing procedures.","Company presenting at J.P. Morgan Healthcare Conference on January 13, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000034","json":"https://secwatch.observer/filing/0001599298-25-000034.json","markdown":"https://secwatch.observer/filing/0001599298-25-000034.md","text":"https://secwatch.observer/filing/0001599298-25-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000034/0001599298-25-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000034/smmt-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:21:43.892957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}